60
Participants
Start Date
October 1, 2019
Primary Completion Date
May 10, 2020
Study Completion Date
May 24, 2020
Nerivio
Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
NYU Langone-Health, New York
Children's Hospital of Philadelphia (CHOP), Philadelphia
PANDA neurology, Atlanta
Clinical Trials Solutions, Hialeah
Nicklaus children hospital, Miami
Cincinnati Children's Hospital Medical Center, Cincinnati
Children Mercy Kansas City, Kansas City
Children Hospital New Orleans, New Orleans
Mercury Clinical Research, Houston
Texas Children's Hospital, Baylor College of Medicine, Houston
Children's Hospital Colorado, Aurora
DENT neurology clinic, Amherst
Lead Sponsor
Theranica
INDUSTRY